Replimune Group, Inc.
Replimune Group, Inc. (REPL) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · REPL · as of Jun 8, 2026
Key Statistics
Explore Replimune Group, Inc. Data
repl stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 15 · Buy rate: 46.7%
The REPL analyst consensus is Buy, based on ratings from 15 Wall Street analysts over the past 3 months. The average 12-month price target is $14.00, representing +47.84% upside from the current price of $9.47.
Competitors & Peers
repl competitorsREPL
ARVN
ATXS
AVBP
DNA
IOVAStock Performance
Full HistoryAbout Replimune Group, Inc.
Replimune Group, Inc. a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that a…
what is replimune group, inc. · repl stock overview · replimune group, inc. company profile · who is replimune group, inc. ceo · repl NASDAQ · replimune group, inc. headquarters · replimune group, inc. business segments
About Stock Overview & Key Data
Replimune Group, Inc. (REPL) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 20, 2018. As of the latest trading session, REPL stock price is $9.47, with a market capitalization of $782.0M. The stock has returned -6.97% over the past 12 months and -2.57% year-to-date.
According to 15 Wall Street analysts, the consensus rating for Replimune Group, Inc. stock is Buy, with an average 12-month price target of $14.00. In fiscal year 2025, Replimune Group, Inc. reported revenue of — and net income of -$247.3M. For detailed data — including Replimune Group, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Replimune Group, Inc. (REPL) stock price is $9.47. The stock is traded on NASDAQ under the ticker symbol REPL. The 52-week range is $1.50 – $13.24.